Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxirane SCHEMBL15286473 | 0.87 | — | — | |
| SCHEMBL17767389 | 0.82 | TP53 (0.61) | TP53TSHRALDH1A1SLC7A5RNPEP | |
| SCHEMBL2531259 | 0.82 | TP53 (0.61) | TP53TSHRALDH1A1SLC7A5RNPEP | |
| Hydrogen Peroxide SCHEMBL28852493 | 0.82 | — | — | |
| SCHEMBL4640114 | 0.82 | TP53 (0.61) | TP53TSHRALDH1A1SLC7A5RNPEP | |
| SCHEMBL5940223 | 0.82 | TP53 (0.61) | TP53TSHRALDH1A1SLC7A5RNPEP | |
| SCHEMBL405938 | 0.82 | TP53 (0.61) | TP53TSHRALDH1A1SLC7A5RNPEP | |
| SCHEMBL10857351 | 0.82 | — | — | |
| SCHEMBL2774033 | 0.82 | TP53 (0.61) | TP53TSHRALDH1A1SLC7A5RNPEP | |
| SCHEMBL17767367 | 0.82 | TP53 (0.61) | TP53TSHRALDH1A1SLC7A5RNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417156-B2 | Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers | JOHNS HOPKINS UNIVERSITY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20060142377-A1 | Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high selectively, stability and efficacy and methods of making the same | JOHNS HOPKINS UNIVERSITY-LICENSE & TECHNOLOGY DEVE (US) | 2006-06-29 | — | — | US | disclosed |
| WO-2004028476-A2 | ARTEMISININ-DERIVED TRIOXANE DIMERS | JOHNS HOPKINS UNIVERSITY (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142377-A1 | Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high selectively, stability and efficacy and methods of making the same | HCCS, ACIN1, ADH1A | TP53 1140/4885TSHR 3361/4885ALDH1A1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.